Alnylam Pharmaceuticals I...

257.08
-12.94 (-4.79%)
At close: Apr 01, 2025, 3:04 PM

Company Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH.

Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.

Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.

It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc.

The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. logo
Country United States
IPO Date Jun 1, 2004
Industry Biotechnology
Sector Healthcare
Employees 2,230
CEO Dr. Yvonne L. Greenstreet M.B.A., M.D.

Contact Details

Address:
675 West Kendall Street
Cambridge, Massachusetts
United States
Website https://www.alnylam.com

Stock Details

Ticker Symbol ALNY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001178670
CUSIP Number 02043Q107
ISIN Number US02043Q1076
Employer ID 77-0602661
SIC Code 2834

Key Executives

Name Position
Dr. Yvonne L. Greenstreet M.B.A., M.D. Chief Executive Officer & Director
Jeffrey V. Poulton M.B.A. Chief Financial Officer & Executive Vice President
Robert W. Hesslein Esq., J.D. Executive Vice President, Chief Legal Officer & Corporate Secretary
Christine Regan Lindenboom Chief Corporate Communications Officer
Dr. Kevin Joseph Fitzgerald Ph.D. Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development
Dr. Phillip A. Sharp Ph.D. Co-Founder, Member of the Scientific Advisory Board & Independent Director
Dr. Pushkal P. Garg M.D. Chief Medical Officer and Executive Vice President of Development & Medical Affairs
Piyush Sharma J.D. Chief Ethics & Compliance Officer
Timothy J. Maines Chief Technical Operations & Quality Officer
Tolga Tanguler M.B.A. Executive Vice President & Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 25, 2025 4 Filing
Mar 25, 2025 4 Filing
Mar 24, 2025 ARS Filing
Mar 24, 2025 DEFA14A Filing
Mar 24, 2025 DEF 14A Filing
Mar 21, 2025 8-K Current Report
Mar 14, 2025 4 Filing
Mar 14, 2025 PRE 14A Filing
Mar 05, 2025 8-K Current Report
Mar 05, 2025 4 Filing